Lorcaserin article in the Formulary Journal

Along with a peer-reviewed report and editorial in the well-respected New England Journal of Medicine, another positive article about Lorcaserin has been published in the Formulary Journal, a peer-reviewed drug management journal for managed-care and hospital decision-makers.

http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Lorcaserin-A-novel-selective-5-HT2C-receptor-agoni/ArticleStandard/Article/detail/673923

ARNA shares gain on VVUS' Qnexa rejection

http://www.businessweek.com/ap/financialnews/D9H09AV80.htm

As usual, some analysts really don't get it.

Separately, Barclay Capital analyst Dr. Jim Birchenough maintained a more conservative "Equal Weight" rating on Arena, saying the FDA seems to have a high hurdle for new obesity drugs and lorcaserin could face its own issues with regulators. Those issues could include adequacy of weight loss and heart valve risks.

According to the recently released New England Journal of Medicine article on Lorcaserin:

http://content.nejm.org/cgi/content/short/363/3/245

Serial echocardiography was used to identify patients in whom valvulopathy (as defined by the Food and Drug Administration) developed.

Among 2472 patients evaluated at 1 year and 1127 evaluated at 2 years, the rate of cardiac valvulopathy was not increased with the use of lorcaserin.

Lorcaserin video

Lorcaserin's visibility is increasing with the peer-reviewed article in the New England Journal of Medicine, as indicated in this video.



http://www.youtube.com/watch?v=6d1y25lsa4I